TxCell names new CEO
This article was originally published in Scrip
Executive Summary
Biotechnology company TxCell, which develops personalized cell-based immunotherapies using for chronic inflammatory and autoimmune diseases, has named Damian Marron chief executive officer. Prior to joining the Valbonne, France-based firm, Mr Marron was CEO of clinical stage biotechnology company Cytheris. Furthermore, from 2008-2012 he was CEO of Trophos. Under his tenure, Trophos spearheaded a group of major EU funded consortia of leading global experts and specialists working on a range of orphan diseases. Mr Marron succeeds Francois Meyer who has now been appointed executive chair of the TxCell's board of directors.
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.